GSK long-acting HIV injection succeeds in study
The long-acting needle-based combination of its drug cabotegravir and Janssen’s treatment rilpivirine met its main goal in the study, which was testing the regimen in adults with HIV-1 whose virus was suppressed.
Profit after tax soared to £3.62 billion last year compared with £1.53 billion in 2017 as the multinational paid less tax under US President Donald Trump's reforms.353 days ago
The interest in home DNA tests is part of a wider drive by drugmakers to tap into a range of anonymised patient data.541 days ago
GSK’s majority-owned ViiV Healthcare unit had reported success from the two so-called GEMINI studies last month but details were only unveiled at the International Aids Conference in Amsterdam.551 days ago
The executive refused to attend the company’s quarterly performance improvement plan.1885 days ago